{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:59:38Z","timestamp":1778180378370,"version":"3.51.4"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>The authors present the case of a critically ill morbidly obese patient (body mass index, 51.2 kg\/m<jats:sup>2<\/jats:sup>) who suffered from methicillin-resistant <jats:italic toggle=\"yes\">Staphylococcus epidermidis<\/jats:italic>, and <jats:italic toggle=\"yes\">Candida albicans<\/jats:italic> bloodstream infections. Initial treatment with caspofungin and daptomycin was deemed inappropriate, because blood cultures remained positive for both isolates after 14 days. The clinical pharmacological consultant suggested adding fluconazole and ceftobiprole to the ongoing antimicrobial therapy, and starting a real-time therapeutic drug monitoring program of daptomycin, ceftobiprole, and fluconazole, aimed at optimizing plasma exposures. Punctual minimum inhibitory concentration knowledge on the clinical isolates allowed attainment of the desired pharmacodynamic efficacy targets. Within few days, the patient greatly improved, as blood cultures became negative, and the inflammatory markers decreased to near normal values. This is a proof-of-concept of the importance of a therapeutic drug monitoring-based multidisciplinary approach in the proper management of complex antimicrobial therapy in special populations.<\/jats:p>","DOI":"10.1097\/ftd.0000000000000740","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T15:12:19Z","timestamp":1581347539000},"page":"349-352","source":"Crossref","is-referenced-by-count":10,"title":["Real-Time Therapeutic Drug Monitoring-Based Pharmacokinetic\/Pharmacodynamic Optimization of Complex Antimicrobial Therapy in a Critically Ill Morbidly Obese Patient. Grand Round\/A Case Study"],"prefix":"10.1097","volume":"42","author":[{"given":"Pier Giorgio","family":"Cojutti","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Udine;"},{"name":"Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital of Udine, ASUFC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Carnelutti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Santa Maria della Misericordia University Hospital of Udine, ASUFC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mattelig","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care, Santa Maria della Misericordia University Hospital of Udine, ASUFC; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assunta","family":"Sartor","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Microbiology, Santa Maria della Misericordia University Hospital of Udine, ASUFC, Udine, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pea","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Udine;"},{"name":"Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital of Udine, ASUFC;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13054-017-1774-2","article-title":"Plasma concentrations of caspofungin in a critically ill patient with morbid obesity","volume":"21","author":"Ferriols-Lisart","year":"2017","journal-title":"Crit Care."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.01527-09","article-title":"Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods","volume":"54","author":"Kiraz","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1592\/phco.27.12.1711","article-title":"Candida endophthalmitis: focus on current and future antifungal treatment options","volume":"27","author":"Khan","year":"2007","journal-title":"Pharmacotherapy."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1128\/AAC.00296-07","article-title":"Correlation of the MIC and dose\/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia","volume":"51","author":"Rodriguez-Tudela","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1128\/AAC.01088-16","article-title":"Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients","volume":"60","author":"Starr","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1128\/AAC.00059-07","article-title":"Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin","volume":"51","author":"Pai","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/phar.2157","article-title":"A fixed versus weight-based dosing strategy of daptomycin may improve safety in obese adults","volume":"38","author":"Butterfield-Cowper","year":"2018","journal-title":"Pharmacotherapy."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1345\/aph.1P745","article-title":"TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient","volume":"45","author":"Pea","year":"2011","journal-title":"Ann Pharmacother."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1128\/AAC.02967-15","article-title":"Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations","volume":"60","author":"Bhavnani","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/jac\/dku236","article-title":"Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes","volume":"69","author":"Barber","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s40262-016-0418-z","article-title":"Pharmacokinetics and dosing of ceftobiprole medocaril for the treatment of hospital- and community-acquired pneumonia in different patient populations","volume":"55","author":"Torres","year":"2016","journal-title":"Clin Pharmacokinet."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","article-title":"What antibiotic exposures are required to suppress the emergence of resistance for gram-negative bacteria? A systematic review","volume":"58","author":"Sumi","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/phar.2023","article-title":"Comprehensive guidance for antibiotic dosing in obese adults","volume":"37","author":"Meng","year":"2017","journal-title":"Pharmacotherapy."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:31:11Z","timestamp":1692052271000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000740","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}